Outcome of retinopathy in chronic hepatitis c patients treated with peginterferon and ribavirin

Digestive Diseases and Sciences

Volumn 55, Issue 2, 2010, Pages 452-457

  Mehta, Nilesh ^a   Murthy, Uma K ^a   Kaul, Vivek ^b   Alpert, Samuel ^a   Abruzzese, Gerald ^a   Teitelbaum, Charles ^a  

^a SYRACUSE VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis C; Complications of peginterferon therapy; Cotton wool spots; Intra retinal hemorrhage; Peginterferon; Pegylated interferon; Retinopathy

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EYE EXAMINATION; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINOPATHY; RISK FACTOR; TREATMENT OUTCOME; WOOL; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; RETINA DISEASE;

ANTIVIRAL AGENTS; DRUG CARRIERS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETINAL DISEASES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 76849087847     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0721-8     Document Type: Article

References (16)

1. Global surveillance, control of hepatitis C 1999 Report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium J Viral Hepat 6 1 35 47 10.1046/j.1365-2893.1999. 6120139.x (Pubitemid 29077623)
2. D Siagris N Pharmakakis M Christofidou JK Petropoulos C Vantzou A Lekkou CA Gogos C Labropoulou-Karatza 2002 Keratoconjunctivitis sicca and chronic HCV infection Infection 30 4 229 233 10.1007/s15010-002-2085-2 10.1007/s15010-002- 2085-2 1:STN:280:DC%2BD38vnsVKgug%3D%3D 12236567
3. S Hayasaka Y Nagaki M Matsumoto S Sato 1998 Interferon associated retinopathy Br J Ophthalmol 82 3 323 325 10.1136/bjo.82.3.323 10.1136/bjo.82.3.323 1:STN:280:DyaK1c3msFentg%3D%3D 9602634
4. T Kawano M Shigehira H Uto T Nakama J Kato K Hayashi T Maruyama T Kuribayashi T Chuman T Futami H Tsubouchi 1996 Retinal complications during interferon therapy for chronic hepatitis C Am J Gastroenterol 91 2 309 313 1:CAS:528:DyaK28XhvVWnt7g%3D 8607498
5. K Jain WC Lam S Waheeb Q Thai J Heathcote 2001 Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin Br J Ophthalmol 85 10 1171 1173 10.1136/bjo.85.10.1171 10.1136/bjo.85.10.1171 1:STN:280:DC%2BD3MritFyjsw%3D%3D 11567959 (Pubitemid 32929539)
6. JA Schulman C Liang LM Kooragayala J King 2003 Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin Ophthalmology 110 2 437 442 10.1016/S0161-6420(02)01741-4 12578794 (Pubitemid 36187441)
7. R Wilson 2004 Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection J Clin Gastroenterol 8 38 717 722 10.1097/01.mcg.0000135897.30038.16 10.1097/01.mcg.0000135897.30038.16 (Pubitemid 39096805)
8. C Okuse H Yotsuyanagi Y Nagase Y Kobayashi K Yasuda K Koike S Iino M Suzuki F Itoh 2006 Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C World J Gastroenterol 12 23 3756 3759 1:CAS:528:DC%2BD28Xntl2kt7o%3D 16773695
9. L d' Alteroche S Majzoub AI Lecuyer MP Delplace Y Bacq 2006 Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis J Hepatol 44 1 56 61 10.1016/j.jhep.2005.07.026 10.1016/j.jhep.2005.07.026 (Pubitemid 41772516)
10. JA Chisholm G Williams E Spence S Parks D Keating M Gavin PR Mills 2005 Retinal toxicity during pegylated alfa interferon therapy for chronic hepatitis C; a multifocal electroretinogram investigation Aliment Pharmacol Ther 21 6 723 732 10.1111/j.1365-2036.2005.02365.x 10.1111/j.1365-2036.2005.02365.x 1:CAS:528:DC%2BD2MXjs1OntLY%3D 15771758 (Pubitemid 40469000)
11. H Saito H Ebinuma H Nagata Y Inagaki Y Saito K Wakabayashi T Takagi M Nakamura H Katsura Y Oguchi H Ishii 2001 Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C Liver 21 3 192 197 10.1034/j.1600-0676.2001.021003192.x 10.1034/j.1600-0676. 2001.021003192.x 1:CAS:528:DC%2BD3MXltFWqsrY%3D 11422782 (Pubitemid 32586577)
12. ME Briggs C Baker R Hall JM Gaziano D Gagnon N Bzowej TL Wright 2001 Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration Medical Center Hepatology 34 6 1200 1205 10.1053/jhep.2001.29303 10.1053/jhep.2001.29303 1:STN:280:DC%2BD3MnosV2qsA%3D%3D 11732010 (Pubitemid 33096593)
13. T Abe A Nakajima N Satoh T Koizumi S Sakuragi T Ono M Komatsu O Masamune 1995 Clinical characteristics of hepatitis C virus-associated retinopathy Jpn J Ophthalmol 39 4 411 419 1:STN:280:DyaK283ksV2nsw%3D%3D 8926649
14. FM Cuthbertson M Davies M Mckibbin 2004 Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 88 12 1518 1520 10.1136/bjo.2004.043968 10.1136/bjo.2004.043968 1:STN:280:DC%2BD2crnvFSitw%3D%3D 15548803 (Pubitemid 39573588)
15. NN Malik HG Sheth N Ackerman N Davies SM Mitchell 2008 A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK Br J Ophthalmol 92 2 256 258 10.1136/bjo.2006.106278 10.1136/bjo.2006.106278 1:STN:280: DC%2BD1c%2FmvFWjtQ%3D%3D 17962387 (Pubitemid 351224106)
16. T Kawano M Shigehira H Uto T Nakama J Kato K Hayashi T Maruyama T Kuribayashi T Chuman T Futami H Tsubouchi 1996 Retinal complications during interferon therapy for chronic hepatitis C Am J Gastroenterol 91 2 309 313 1:CAS:528:DyaK28XhvVWnt7g%3D 8607498